Are glucagon‐like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV?

Abstract

Weight gain is a current concern for people living with HIV (PLWH) on antiretroviral therapy (ART) [1]. Limited data are available on glucagon-like peptide 1 receptor agonists (GLP-1RAs) in PLWH [1][2][3][4]. GLP-1RAs are effective in type 2 diabetes and they have also been approved by Food and Drug Administration and the European Medicines Agency for chronic weight management. In Italy, GLP-1RAs are currently marketed only for type 2 diabetes.Our aim was to evaluate the changes in body weight (BW) and body mass index (BMI) in diabetic PLWH on ART after the introduction of GLP-1RAs.